Lonza enters the exosome therapy space with acquisition of still-new Codiak site
In anticipation of tackling the manufacturing problems that come with exosome therapeutics head on, Codiak BioSciences built a 12,000-square-foot manufacturing site in Lexington, MA. Tuesday, it announced that it will hand over the reins to a powerhouse CDMO.
Swiss manufacturer Lonza will acquire IP rights and the facility from Codiak in exchange for $65 million worth of manufacturing services, the companies said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.